Laurence de Schoulepnikoff
Chief Operating Officer at OSE IMMUNOTHERAPEUTICS
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dominique Costantini | M | 69 | 20 years | |
| Anne-Laure Autret-Cornet | F | - | 8 years | |
| Maryvonne Hiance | F | 75 | 8 years | |
| Nicolas Poirier | M | 42 | 8 years | |
| Eric Jean Marie Leire | M | 66 | 1 years | |
| Alexandre LeBeaut | M | 66 | 2 years | |
| Elsy Boglioli Hofman | F | 42 | 3 years | |
| Gérard Tobelem | M | 76 | 10 years | |
| Giuseppina Caligiuri | M | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | 6 years |
| Brigitte Dreno | M | 71 | 7 years | |
| Didier Hoch | M | 68 | 8 years | |
| Silvia Comis | M | - | 3 years | |
| Thomas Guillot | M | - | - | |
| Fraser Murray | M | 53 |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
| Sophie Fay | F | - | - | |
| Sarah Holland | F | 61 |
Swiss Healthcare Licensing Group
| 5 years |
| Benoit Barteau | M | - |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
| Sylvie Détry | F | - | - | |
| Héloïse Deliquiet | F | 55 |
Swiss Healthcare Licensing Group
| - |
| Françoise Bono | M | - | 3 years | |
| Alain Huriez | M | 62 |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
| Linda Lebon | F | 58 | 3 years | |
| Jean-Pascal Conduzorgues | M | - | - | |
| Erik van den Berg | M | 51 |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
| Helmut H. Kessmann | M | 64 |
Swiss Healthcare Licensing Group
| 6 years |
| Klaus Breiner | M | - |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
| Jean Jacques Mention | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alexis Peyroles | M | - | 6 years | |
| Jean-Patrick Demonsang | M | 71 | 9 years | |
| Alexis Vandier | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 27 | 90.00% |
| Switzerland | 3 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laurence de Schoulepnikoff
- Personal Network
